According to Prof. Quang, although Vietnam already had access to pembrolizumab-based immunotherapies from major pharmaceutical companies, their high cost made them less accessible. Once procurement and insurance procedures are completed, the drug will be introduced into hospital treatment protocols. Regarding lung cancer diagnosis, Prof. Quang emphasized the growing importance of early screening, particularly for high-risk groups. Looking ahead, Prof. Quang said that the health sector will focus on expanding early lung cancer screening among high-risk populations - such as the elderly, long-term smokers, and those exposed to secondhand smoke. Prof. Quang reiterated that tobacco remains the primary cause of lung cancer, accounting for over 90% of all cases, including both active and passive smokers.

Source: VietNamNet News February 06, 2026 01:06 UTC